Remove tag health-canada
article thumbnail

Risk-sharing agreements are growing at a rate of 24%

Pharmaceutical Technology

This is not the first treatment to come with a high price tag. Their widespread agreements are established in the UK, followed by seven additional countries (Australia, France, Netherlands, Spain, Poland, Italy, and Canada). million, according to GlobalData’s Price Intelligence (POLI), making it the most expensive drug in the world.

article thumbnail

Grand Rounds April 21, 2023: Personalised Cooler Dialysate for Patients Receiving Maintenance Haemodialysis (MyTEMP): A Pragmatic, Cluster-randomised Trial (Amit Garg, MD, MA, FRCPC, FACP, PhD; Stephanie N. Dixon, PhD MSc)

Rethinking Clinical Trials

The MyTEMP trial is a pragmatic, cluster randomized controlled trial in Ontario, Canada, to determine if adopting a default center-wide policy of personalized cooler dialysate is superior to a standard temperature dialysate of 36.5 degrees Celsius.

Trials 130
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Merck Announces Withdrawal and Refiling under the Hart-Scott-Rodino Act and Extension of Tender Offer to.

The Pharma Data

Merck known as MSD outside the United States and Canada, moment blazoned that it has withdrawn its Premerger Announcement and Report Form under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “ HSR Act”), in connection with Merck’s pending accession of Acceleron PharmaInc. Nasdaq XLRN).

article thumbnail

First Gene Therapy Approved for Hemophilia B + World AMR Awareness Week – Xtalks Life Science Podcast Ep. 88

XTalks

Hear more about the therapy and how the high price tag of the new drug is actually lower than the cost of treating Hemophilia B patients over their lifetimes with current conventional treatments. Read the full articles here: Hemgenix Approved as First Gene Therapy for Hemophilia B.

article thumbnail

Omicron Designated as a Variant of Concern by WHO: What We Know About It So Far

XTalks

The World Health Organization (WHO) has declared the new variant of SARS-CoV-2 found in South Africa, first referred to as B.1.1.529, The technical advisory group on SARS-CoV-2 virus evolution (TAG-VE) met on Friday to discuss B.1.1.529, 1.1.529, two days after it was first reported to the global health agency by South Africa.

article thumbnail

A roadmap for adopting New Science 

pharmaphorum

The adoption of New Science – a unique combination of the best in science and health technology that address significant unmet patient needs – is delivering more precise and effective treatments, but often at a higher price tag, according to new research. These will all help pay for New Science. .

article thumbnail

Grand Rounds July 29, 2022: Effect of Early Treatment With Single-Dose Pegylated Interferon Lambda Among Patients With COVID-19: Results From The TOGETHER Trial (Edward Mills, PhD, FRCP; Jeffrey S. Glenn, MD, PhD)

Rethinking Clinical Trials

Department of Health Research Methods, Evidence & Impact. McMaster University, Canada. The arm evaluating Peginterferon Lambda is a multicenter, investigator sponsored, randomized placebo-controlled Phase 3 study in Brazil with 12 sites and Canada (5 sites). Edward Mills, PhD, FRCP. Glenn, MD, PhD. Stanford University.

Trials 130